Scale-up production, expand US ‑Sales: JENETRIC GmbH pursues ambitious goals with the third funding round
The German biometrics company was able to inspire its investors to participate in another investment round and win a new…
Innovative Thuringian companies connect with companies in Chicago and Detroit
Together with LEG Thüringen, the German-American Chamber of Commerce Chicago and Molex Inc., bm|t organized a business trip to Chicago…
InflaRx raises EUR 31 million (US$ 34M) in a Series C financing round to foster complement inhibitor development
InflaRx, the biopharmaceutical company developing new therapeutics in the terminal complement space, announced today that it has raised EUR 31…
Highest security and easy usability — JENETRIC receives award for its user-friendly fingerprint technology
JENETRIC GmbH won first prize at the 12th IQ Innovation Awards of Central Germany in the category of information technology. Out of 61 competing innovators, JENETRIC…
Investor Days Thuringia brings innovative founders and investors together in Erfurt
600 guests, including 70 investors and 69 founders, came together for 2 jam-packed days at this year's Investor Days Thuringia. The…
High-Tech Gründerfonds (HTGF) und bm|t renew their coöperation agreement
HTGF and bm|t have renewed their cooperation agreement and have thus reinforced their commitment to supporting and financing young Thuringian…
Evonik and JeNaCell intensify their coöperation
Evonik Chairman Klaus Engel visits BioInstrumentation Center in Jena for on-site briefing on production expansion Engel: “Outstanding example of industrial…
The first “Navigation System” for drugs – soon to be developed in Thuringia
Drugs that target only the diseased organs and cells of the body, thereby causing fewer side effects – this is…
eZono appoints Sungmo Lee as new CEO
eZono’s supervisory board has appointed Sungmo Lee as the company’s Chief Executive Officer effective February 1, 2016. Mr. Lee succeeds…
InflaRx announces positive top-line results from phase II‑a of the SCIENS trial investigating IFX‑1, a first-in-class, anti-complement C5a antibody
Jena, Germany – InflaRx, a biopharmaceutical company developing new therapeutics in the terminal complement space, announced positive resultstoday from its…